Navigation Links
Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer -

LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- Response Genetics, Inc. today announced that positive Phase III clinical data published in the July 1 issue of the Journal of Clinical Oncology suggests that low expression of the biomarker Excision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsies with advanced non-small cell lung cancer (NSCLC) predicts for sensitivity to cisplatin-based chemotherapy. ERCC-1 is an enzyme involved in repair of DNA strand breaks such as those caused by cisplatin. The analysis of ERCC-1 levels in this study was conducted by Response Genetics using its RGI-1 technology. Data from previous studies published by the Company in Clinical Cancer Research 2002 and Annals of Oncology 2006 showing that ERCC-1 was associated with tumor sensitivity to cisplatin formed the basis for the present study. This is the first prospective study using a biomarker to predict chemotherapy response in lung cancer. These findings support the use of measurement of ERCC-1 for individualizing therapies for lung cancer patients.

The Phase III multicenter, randomized study was designed to determine the overall response rate (complete plus partial responses) of patients with stage IIIb or IV NSCLC to cisplatin-based therapy by determining levels of the biomarker ERCC-1 mRNA in their paraffin-embedded tissue biopsy before administering treatment. Patients were prospectively assigned treatment to a cisplatin or non-cisplatin-based chemotherapy depending on whether the ERCC-1 gene expression in their tumor sample was above or below a specific threshold. Patients were assigned to one of two arms in this trial. The control arm consisted of all patients receiving cisplatin-based therapy. Patients in the "genotypic" arm were separated by levels of ERCC-1. Cisplatin-based therapy (docetaxel/cisplatin) was assigned to patients with low
'"/>




Page: 1 2 3 4

Related medicine technology :

1. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
2. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
5. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
6. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
7. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
8. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
9. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
10. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
11. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues

Post Your Comments:
(Date:11/20/2009)...wire-FirstCall/ -- Biotel Inc. (OTC Bulletin Board...ded September 30, 2009 with net earnings of $128,0...263,000. This compares to net earnings of $328,00...68,000 for the first quarter of last year. ,, C...sident and CEO Steve Springrose said: "Biotel enjo...
(Date:11/20/2009)...20 BD (Becton, Dickinson...ompletion of its acquisition of HandyLab, Inc., an...nd manufactures molecular diagnostic assays and au...yLab announced an exclusive agreement for BD to de...ndyLab Jaguar(TM) platform, the first fully integr...
(Date:11/19/2009)...RNewswire/ -- Warner Chilcott plc (Nasdaq: WCRX )...ounced secondary offering of 20,000,000 of its ord...r share. The selling shareholders include funds a... Banking, J.P. Morgan Partners (advised by CCMP Ca...ther institutional investors and members of the Co...
Breaking Medicine Technology:Biotel Announced Profitable First Quarter Ended September 30, 2009 2BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4MUHC researcher awarded 24500 000 to study pathogenesis of infectious disease 48951 1MUHC researcher awarded 24500 000 to study pathogenesis of infectious disease 48951 2TRAPping proteins that work together inside living cells 8843 1TRAPping proteins that work together inside living cells 8843 2TRAPping proteins that work together inside living cells 8843 3Shortcuts of the mind lead to miscalculations of weight and caloric intake says Penn study 8840 1Shortcuts of the mind lead to miscalculations of weight and caloric intake says Penn study 8840 2Shortcuts of the mind lead to miscalculations of weight and caloric intake says Penn study 8840 3
...BEDFORD, Mass., Nov. 13 Hologic, Inc.,(Nasdaq: H...ier of premium,diagnostics, medical imaging system...ealthcare needs of women, today announced the resu... trial. The Cervista HPV high-risk,test is current...cted to be,launched in the European Union (EU) ear...
...Groundbreaking Research Finds Statins Cut Risk of ...iovascular Disease,is the leading cause of death a...reds of millions of dollars and causing untold suf...fatal disease - even among those who,weren,t thoug...lions of people could cut their risk of a,heart at...
Other Medicine Technology:Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 3Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 4Seniors Can Be Heartened by New Study on Statins 2
(Date:11/20/2009)...USNewswire/ -- The following is a statement by Cha...h Care Association: ,, "The Nevada Health Care ...rity Leader Harry Reid for his leadership in takin...ecting every Nevada seniors, ongoing access to qua...h and viability of our state,s vital frontline wor...
(Date:11/20/2009)...n with chronic kidney disease often fail to detect... increasing a child,s risk for serious heart probl...dren,s Center and other institutions. A report of ...ican Society of Nephrology. , Researchers comp...egular doctor visits to readings obtained via a sp...
(Date:11/20/2009)...day supply, study finds , , FRIDAY, Nov....y of prescription drugs is up to one-third cheaper...w study. , U.S. researchers analyzed 26,852 pre...005, and found that patients who bought a three-mo...average 29 percent in out-of-pocket costs. After t...
(Date:11/20/2009)...creased food insecurity as many face problem of hu.../ -- Project Bread, the state,s leading anti-hunge... annual status report on hunger in the Commonwealt..., caused by high unemployment, point to 554,000 pe...ood insecurity has found its way into middle class...
(Date:11/20/2009)...RNewswire-USNewswire/ -- The Louisiana Associati...anians could experience higher health care premium...ed by Congress should become law. ,, According ...ouisiana health plans have supported comprehensive...ional debate. Our plans have offered significant ...
Breaking Medicine News(10 mins):Health News:High blood pressure easy to miss in children with kidney disease 2Health News:Three-Month Supply Lowers Drug Costs 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 3Health News:554,000 in Massachusetts Struggle to Put Food on the Table 4Health News:Congressional Health Care Reform Proposals Would Make Health Care More Expensive, Reduce Benefits for Louisianians 2
...esident Obama decided on Kansas Gov. Kathleen Sebe... Health and Human Services. , , (Logo: http:... , , Tony Perkins, President of FRC Action, the l... up his Health and Human Services Department (HHS)...
... but most people believe they are meaningful , ...worldwide subscribe to the belief that you are wha...lished in February,s Journal of Personality and S...rnegie Mellon University, said in an American Psyc...
...an respond intelligently to difficult negotiation ... integrate effective counter strategies into their...al forum for sales process improvement hosts a web...uces risk. , Atlanta, Ga....
...ous studies have raised questions regarding differ... on a weekend compared to weekdays. In fact, a gro...ated an association between admission to hospitals...ments and procedures. , Two recent studies publis...
...arch 1 issue of the journal SLEEP shows that a s...l for addressing adolescent sleep problems, given...otential for promoting healthy sleep knowledge and... a statistical increase in students, knowledge of ...
...tables such as broccoli and cabbage could be a pot...earchers. Tests on mice suggest that these compoun...e safely and effectively than conventional therapy... and dermatology, Penn State College of Medicine. ...
Other Medicine News:Health News:FRC Action Questions President Obama's Choice of Gov. Sebelius for HHS 2Health News:Across All Cultures, Dreams Affect Behavior 2Health News:How to Increase Sales Margin 1 Percent to 10 Percent and Lower Your Risk by Building a Negotiation Strategy into Your Sales Process 2Health News:How to Increase Sales Margin 1 Percent to 10 Percent and Lower Your Risk by Building a Negotiation Strategy into Your Sales Process 3Health News:Patients with GI bleeding admitted on the weekend have higher death rate 2Health News:Patients with GI bleeding admitted on the weekend have higher death rate 3Health News:School-based intervention is a promising model for improving adolescent sleep habits 2Health News:School-based intervention is a promising model for improving adolescent sleep habits 3Health News:Vegetable-based drug could inhibit melanoma 2
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: